Stock comparison
BIOGEN INC. is 19.2x more valuable than Inhibrx, Inc. by market capitalization ($29.37 B vs $1.53 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
BIIB is larger
BIOGEN INC. is 19.2x more valuable than Inhibrx, Inc. by market capitalization ($29.37 B vs $1.53 B).
Market value leader
BIIB
BIOGEN INC. is 19.2x more valuable than Inhibrx, Inc. by market capitalization ($29.37 B vs $1.53 B).
Revenue leader
BIIB
INBX: $1.80M vs BIIB: $9.89B.
Profit leader
BIIB
INBX: -$241.36M vs BIIB: $1.29B.
Margin leader
BIIB
INBX: -13408.9% vs BIIB: 13.1% net margin.
| Metric | INBX | BIIB |
|---|---|---|
| Market cap | $1.53 B | $29.37 B |
| US-listed rank | #2346 | #476 |
| Revenue (latest FY) | $1.80M | $9.89B |
| Net income (latest FY) | -$241.36M | $1.29B |
| Net margin | -13408.9% | 13.1% |
| P/E (trailing FY) | - | 22.7x |
| SEC filings | 261 | 2,690 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
BIOGEN INC. is 19.2x more valuable than Inhibrx, Inc. by market capitalization ($29.37 B vs $1.53 B).
Full pages: Inhibrx, Inc. and BIOGEN INC., or browse the full rankings.